

Table 1:

**Accrual Summary for First Transplants
with Samples Available for Recipient and/or Donor through the NMDP**

Variable	Samples Available for					
	Recipient and Donor		Recipient Only		Donor Only	
	N Eval	N (%)	N Eval	N (%)	N Eval	N (%)
Number of cases		12536		2700		2105
Number of centers		161		144		156
Age, median (range), years	12536	35 (<1-75)	2700	32 (<1-79)	2105	32 (<1-74)
Age at transplant	12536		2700		2105	
< 10 y		1778 (14)		451 (17)		389 (18)
10-20 y		1681 (13)		406 (15)		305 (14)
20-29 y		1793 (14)		398 (15)		296 (14)
30-39 y		2041 (16)		431 (16)		302 (14)
40-49 y		2389 (19)		533 (20)		366 (17)
≥ 50 y		2854 (23)		481 (18)		447 (21)
Male sex	12536	7323 (58)	2700	1587 (59)	2105	1237 (59)
Karnofsky prior to transplant > 90%	11781	8379 (71)	2576	1801 (70)	1953	1367 (70)
HLA-A, B, DRB1 groups	11749		2465		1867	
0/6 - 2/6		1 (<1)		2 (<1)		0
3/6		18 (<1)		7 (<1)		0
4/6		288 (2)		144 (6)		38 (2)
5/6		2272 (19)		583 (24)		334 (18)
6/6		9170 (78)		1731 (70)		1495 (80)
HLA high resolution typed at HLA -A, -B, -C, -DRB1 and -DQB1	12536	8422 (67)	2700	20 (1)	2105	12 (1)
Disease status at transplant	12536		2700		2105	
Early		3648 (29)		810 (30)		542 (26)
Intermediate		2830 (23)		689 (26)		487 (23)
Advanced		2587 (21)		528 (20)		483 (23)
Non-malignant disease/Other		3471 (28)		673 (25)		593 (28)
Graft type	12536		2700		2105	
Bone marrow		8117 (65)		1889 (70)		1356 (64)
Peripheral blood		4077 (33)		526 (19)		673 (32)
Cord blood		342 (3)		285 (11)		76 (4)

Table 1:

Accrual Summary for First Transplants (*continued*)

Variable	Samples Available for					
	Recipient and Donor		Recipient Only		Donor Only	
	N Eval	N (%)	N Eval	N (%)	N Eval	N (%)
Disease at transplant	12536		2700		2105	
AML		3530 (28)		784 (29)		635 (30)
ALL		2348 (19)		497 (18)		419 (20)
Other leukemia		578 (5)		111 (4)		92 (4)
CML		2437 (19)		589 (22)		350 (17)
MDS/MPS		1426 (11)		265 (10)		221 (11)
Non-Hodgkin's lymphoma		841 (7)		143 (5)		117 (6)
HD-Hodgkin's lymphoma		55 (<1)		8 (<1)		8 (<1)
MYE-plasma cell disorder, MM		94 (1)		21 (1)		10 (<1)
Other malignancies		36 (<1)		7 (<1)		7 (<1)
Breast cancer		4 (<1)		0		0
Severe aplastic anemia		596 (5)		126 (5)		105 (5)
Inherited ab erythro. diff-funct.		31 (<1)		15 (1)		5 (<1)
SCID & other immune deficienc.		224 (2)		50 (2)		55 (3)
Inherited abnormal. of platelets		11 (<1)		3 (<1)		4 (<1)
Inherited disorder of metabolism		201 (2)		54 (2)		39 (2)
Histiocytic disorders		105 (1)		25 (1)		30 (1)
Other		19 (<1)		2 (<1)		8 (<1)
Conditioning regimen	12536		2700		2105	
Myeloablative		9489 (76)		2181 (81)		1568 (74)
Reduced intensity		1917 (15)		340 (13)		345 (16)
Nonmyeloablative		974 (8)		150 (6)		162 (8)
Other		156 (1)		29 (1)		30 (1)
GVHD prophylaxis	12536		2700		2105	
FK506 ± MMF ± MTX ± Steroids ± other		4033 (32)		750 (28)		653 (31)
FK506 ± other		318 (3)		68 (3)		56 (3)
CsA + MTX ± other		4515 (36)		1052 (39)		763 (36)
CsA ± other		1209 (10)		317 (12)		254 (12)
MMF ± other		23 (<1)		7 (<1)		4 (<1)
MTX ± other		88 (1)		10 (<1)		3 (<1)
T-cell depletion		1763 (14)		417 (15)		293 (14)
Other		587 (5)		79 (3)		79 (4)
Donor age, median (range), years	12194	35 (18-61)	2415	34 (18-61)	2029	35 (18-59)
Age of UCB, median (range), years	342	2.9 (0.3-8)	285	3.7 (0.3-11)	76	3.5 (0.3-6)
Donor age	12536		2700		2105	
< 20 (including cord blood)		461 (4)		313 (12)		102 (5)
20-29		3369 (27)		771 (29)		569 (27)
30-39		4602 (37)		917 (34)		756 (36)
40-49		3266 (26)		566 (21)		524 (25)
≥ 50		838 (7)		133 (5)		154 (7)

Table 1:

Accrual Summary for First Transplants (*continued*)

Variable	Samples Available for					
	Recipient and Donor		Recipient Only		Donor Only	
	N Eval	N (%)	N Eval	N (%)	N Eval	N (%)
Donor/recipient sex match	12524		2685		2095	
Male/Male		4805 (38)		991 (37)		818 (39)
Male/Female		2924 (23)		608 (23)		465 (22)
Female/Male		2512 (20)		589 (22)		414 (20)
Female/Female		2283 (18)		497 (19)		398 (19)
Donor/recipient CMV match	12536		2700		2105	
Negative/Negative		3930 (31)		753 (28)		605 (29)
Negative/Positive		3807 (30)		719 (27)		682 (32)
Positive/Negative		1726 (14)		374 (14)		275 (13)
Positive/Positive		2414 (19)		524 (19)		427 (20)
Unknown		659 (5)		330 (12)		116 (6)
Year of transplant	12536		2700		2105	
1987		1 (<1)		0		1 (<1)
1988		63 (1)		4 (<1)		2 (<1)
1989		147 (1)		3 (<1)		5 (<1)
1990		203 (2)		19 (1)		18 (1)
1991		298 (2)		43 (2)		41 (2)
1992		322 (3)		37 (1)		66 (3)
1993		353 (3)		64 (2)		85 (4)
1994		452 (4)		102 (4)		73 (3)
1995		479 (4)		172 (6)		79 (4)
1996		523 (4)		214 (8)		92 (4)
1997		612 (5)		212 (8)		102 (5)
1998		566 (5)		253 (9)		106 (5)
1999		666 (5)		209 (8)		92 (4)
2000		791 (6)		134 (5)		102 (5)
2001		769 (6)		115 (4)		101 (5)
2002		592 (5)		100 (4)		237 (11)
2003		840 (7)		133 (5)		243 (12)
2004		1045 (8)		215 (8)		189 (9)
2005		1222 (10)		219 (8)		168 (8)
2006		1381 (11)		317 (12)		161 (8)
2007		1211 (10)		135 (5)		142 (7)
Median fu of surviving patients, mo	4468	46 (<1-231)	896	60 (1-203)	647	46 (<1-207)

Abbreviations:

BM = bone marrow, **PBSC** = peripheral blood stem cells, **CMV** = cytomegalovirus,
AML = acute myeloid leukemia, **CML** = chronic myeloid leukemia,
MDS/MPS = myelodysplastic syndrome/myeloproliferative syndrome,
NHL = non-Hodgkin lymphoma, **HD** = Hodgkin lymphoma,
MYE = multiple myeloma, **BC** = breast cancer, **SAA** = severe aplastic anemia,
SCID = severe combined immunodeficiency, **Bu** = busulfan, **Bu/Cy** = busulfan/cytoxan,
TBI = total body irradiation, **FLU** = fludarabine, **CSA** = cyclosporine A,
MTX = methotrexate, **TCD** = T cell depletion